<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02154269</url>
  </required_header>
  <id_info>
    <org_study_id>PCL07/12</org_study_id>
    <nct_id>NCT02154269</nct_id>
  </id_info>
  <brief_title>A Prospective, Phase II Clinical Trial for Evaluation of G- CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy</brief_title>
  <official_title>Prospective, Double-blind, Randomized, Placebo-controlled Phase II Clinical Trial for Evaluation of G-CSF in Patients With Chronic Chagas Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Sao Rafael</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Sao Rafael</source>
  <oversight_info>
    <authority>Brazil: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of treatment with G-CSF in
      patients with chronic heart failure secondary to Chagas disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>NYHA (New York Heart Association) functional class improvement</measure>
    <time_frame>6, 9 and 12 months after the therapy with G-CSF</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients will undergo periodic clinical evaluations in order to identify improvement on NYHA classification for heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of cardiovascular function measured by transthoracic echocardiography</measure>
    <time_frame>6 and 12 months after the therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients will be submitted to echocardiography after 6 and 12 months to assess improvements on ventricular function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cardiovascular function measured by cardiac magnetic resonance imaging</measure>
    <time_frame>12 months after therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients will be submitted to a second cardiac magnetic resonance, after 12 months, to assess improvements on left ventricular ejection fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of functional capacity assessed by treadmill test and by 6-minute walk test</measure>
    <time_frame>12 months after the therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients will be submitted to a second treadmill test and 6-minute walk test after 12 months to assess improvement on functional capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of improvement of quality of life</measure>
    <time_frame>6 and 12 months after the therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients will respond to Minnesota Questionnaire to have an evaluation of quality of life after 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of tolerability</measure>
    <time_frame>1, 5, 13, 17, 25, 29, 37 and 41 days and 3, 6, 9 and 12 months after the therapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All patients will be submitted to complete blood counts in several time frames in order to evaluate tolerability to G-CSF injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Chagasic Myocarditis</condition>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with G-CSF (Granulocyte colony stimulating factor)</intervention_name>
    <arm_group_label>G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Chagas' disease confirmed by two serological tests with different
             methodologies;

          -  Diagnosis of Chagas' cardiomyopathy in NYHA functional classes II, III and IV of
             heart failure;

          -  Availability and willingness to participate, given the schedule of the study;

          -  Agreement and signing the written form.

        Exclusion Criteria:

          -  Acute systemic infections

          -  Solid neoplasms, myelodysplastic syndrome, acute or chronic myeloid leukemia,
             confirmed by imaging studies or past medical history;

          -  Valvulopathies with hemodynamic consequences;

          -  Autoimmune, pulmonary, or degenerative diseases, confirmed by imaging studies or past
             medical history;

          -  Severe renal, hepatic or thyroid dysfunction, confirmed by imaging studies or past
             medical history;

          -  Pregnancy (confirmed by examination of β HCG) or lactation;

          -  Known hypersensitivity to G-CSF or to other components of the formula and / or
             hypersensitivity to proteins derived from E. coli.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milena BP Soares, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ticiana F Larocca, MD, Msc</last_name>
    <role>Study Director</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Ribeiro-dos-Santos, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno SF Souza, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Márcia MN Rabelo, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luís Cláudio L Correia, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolina T Macedo, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Milena BP Soares, PhD</last_name>
    <phone>557132816489</phone>
    <email>milenabpsoares@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital São Rafael</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milena BP Soares, PhD</last_name>
      <phone>557132816489</phone>
      <email>milenabpsoares@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Sao Rafael</investigator_affiliation>
    <investigator_full_name>Milena Botelho Pereira Soares</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Chagas disease</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Cell therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chagas Cardiomyopathy</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
